Avoiding hurdles in molecular assay development
Presented By:
Naeem Nathoo
Speaker Biography:
Naeem Nathoo holds a Master’s degree in Biology and Microbiology from Western University in London, Ontario. Naeem joined Thermo Fisher Scientific in 2016 and is currently the Sr OEM Sales Representative, at LSLPG. Naeem has extensive experience in B2B partnerships with bio-incubators, and his deep understanding of developing partnerships for the research, development and validation, and ultimately commercialization phases of the molecular diagnostic journey allow for time savings and operational efficiency.
Webinar:
Avoiding hurdles in molecular assay development
Webinar Abstract:
The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and quality. The need for these types of assays in infectious disease diagnostics has become apparent on a wide scale, but molecular diagnostic testing is also poised to grow in other areas such as genetic testing, prenatal testing, oncology, and pharmacogenomics over the next several years.
Growth in the amount of testing being done in these areas brings additional challenges due to a number of issues such as various sample types, presence of inhibitors, and low sample amounts—all of which contribute to potential poor results due to less than ideal amplification reactions.
This webinar will demonstrate how small changes to assay components (such as enzyme selection) can overcome many of these hurdles during development and significantly impact the overall quality and accuracy of an assay. The presentation will cover specific cases related to SARS-CoV-2 detection, and highlight quality and manufacturing considerations crucial to development of a molecular assay for any target.
LabRoots on Social:
Facebook: / labrootsinc
Twitter: / labroots
LinkedIn: / labroots
Instagram: / labrootsinc
Pinterest: / labroots
SnapChat: labroots_inc